Project BioShield Act of 2004

Project BioShield Act of 2004
U.S. Government · Public domain · source
Shorttitle	Project BioShield Act of 2004
Longtitle	An act to amend the Public Health Service Act to provide protections and countermeasures against chemical, radiological, or nuclear agents that may be used in a terrorist attack against the United States by accelerating the research, development, purchase, and availability of such countermeasures.
Enacted by	108th
Effective date	July 21, 2004
Cite public law	108–276
Acts amended	Public Health Service Act
Introducedin	House
Introducedbill	H.R. 2122
Introducedby	Rep. Joe Barton (R-TX)
Introduceddate	May 19, 2003
Committees	House Energy and Commerce, Senate Health, Education, Labor, and Pensions
Passedbody1	House
Passeddate1	May 20, 2004
Passedvote1	414–2
Passedbody2	Senate
Passeddate2	July 14, 2004
Passedvote2	99–0
Signedpresident	George W. Bush
Signeddate	July 21, 2004

Project BioShield Act of 2004 is a pivotal piece of United States legislation designed to accelerate the development and procurement of medical countermeasures against biological, chemical, radiological, and nuclear threats. Enacted in the wake of the September 11 attacks and the 2001 anthrax attacks, it aimed to address perceived vulnerabilities in the nation's biodefense preparedness. The law established new authorities and dedicated funding to incentivize the pharmaceutical industry to invest in this specialized, high-risk market, fundamentally reshaping the federal government's approach to medical countermeasure acquisition.

Background and legislative history

The impetus for the legislation stemmed from heightened national security concerns following the September 11 attacks and the subsequent 2001 anthrax attacks, which exposed critical gaps in the nation's medical defense arsenal. Prior efforts, like the establishment of the Strategic National Stockpile and initiatives by the National Institute of Allergy and Infectious Diseases, highlighted the need for a more robust and streamlined procurement system. The bill was championed by the George W. Bush administration, with key support from legislators such as Senator Joe Lieberman and Senator Orrin Hatch. It moved swiftly through the United States Congress, receiving overwhelming bipartisan support, and was signed into law by President George W. Bush in July 2004.

Key provisions and authorities

A central provision created a permanent, "no-year" funding mechanism, allowing the Department of Health and Human Services to commit multi-year budgets for advanced development and procurement, a significant departure from annual appropriations cycles. The act also granted the Secretary of Health and Human Services new authority to make "emergency use" determinations, allowing the Food and Drug Administration to authorize unapproved medical products during a declared emergency. Furthermore, it established the Biomedical Advanced Research and Development Authority within the Department of Health and Human Services to manage the advanced development and acquisition of countermeasures.

Implementation and procurement process

Implementation was managed primarily by the newly formed Biomedical Advanced Research and Development Authority in collaboration with the National Institutes of Health and the Centers for Disease Control and Prevention. The procurement process involved identifying priority threats, sponsoring advanced research through contracts, and ultimately purchasing finished products for the Strategic National Stockpile. Early contracts under the act included procurement of a next-generation anthrax vaccine from Emergent BioSolutions and botulism antitoxin from Cangene Corporation. The process has been critiqued for its complexity and the high-risk nature of developing products for a market consisting solely of the U.S. government.

Funding and appropriations

The act initially authorized approximately $5.6 billion over ten years for the procurement of medical countermeasures, a figure later adjusted through subsequent legislation like the Pandemic and All-Hazards Preparedness Act. This funding was separate from the research budgets of agencies like the National Institute of Allergy and Infectious Diseases. The financial commitment was intended to provide a guaranteed market to attract investment from major biotechnology firms such as Bavarian Nordic and pharmaceutical companies. Congressional oversight of these expenditures has been conducted by committees including the Senate Appropriations Committee.

Impact and legacy

The act's legacy is significant, creating a more predictable pathway for biodefense products and leading to the stockpiling of countermeasures for threats like smallpox, anthrax, and botulism. It served as a foundational model for later preparedness laws, including the Pandemic and All-Hazards Preparedness Act and its reauthorizations. Criticisms have focused on procurement delays, high costs, and challenges in maintaining stockpiled products. However, the framework proved crucial during public health emergencies, including the 2009 flu pandemic and the COVID-19 pandemic, where its authorities were used to expedite the development and deployment of therapeutics and vaccines. Category:2004 in American law Category:United States federal biodefense legislation Category:George W. Bush administration initiatives